EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cell lung cancer, uroth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Hodgkin Lymphoma
• Malignant Melanoma
• Mesothelioma
• Non-small Cell Lung Carcinoma
• Renal Cell Carcinoma
• Squamous Cell Carcinoma of the Head and Neck
• Urothelial Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Status: Authorised. Therapeutic area: Melanoma;Hodgkin Disease;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Carcinoma, Transitional Cell;Squamous Cell Carcinoma of Head and Neck;Urologic Neoplasms;Mesothelioma;Colorectal Neoplasms. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 05/03/2026